Promega, CS3695A04, Lumit® C1q Binding Assay

The Ideal Assay to Complement Your Antibody Development Efforts
The Fc region of monoclonal antibodies mediate several effector functions, including complement-dependent cytotoxicity (CDC), through activation of the classical complement pathway. C1q binding to the Fc region is the critical first step in activating this pathway. By quantifying Fc-C1q binding, antibody developers can precisely profile C1q-antibody interactions, predict complement activation kinetics, and accelerate therapeutic antibody selection to ensure both efficacy and safety in therapeutic applications.
Traditional methods to measure C1q binding face several limitations:
Time-consuming incubation steps
Highly variable fluorescent readouts
Low throughput assay set-ups
What does using the Lumit® C1q Binding Assay mean for you?
Get simple, reliable surrogate measurement of CDC potential in under two hours
Analyze multiple antibody isotypes and fine-tune your Fc engineering efforts and select promising candidates quickly
Balance efficacy with safety: achieve sufficient complement activation while minimizing off-target toxicity
Run your samples in a high-throughput and automation friendly design